Abstract:Importance Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer. Observations Breast cancer is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). More than 90% of breast cancers are not metastatic at the time of diagnosis. For people presenting without metastatic disease, therapeutic goals are tumor eradication and preventing recurrence. Triple-negative breast cancer is more likely to recur than the other 2 subtypes, with 85% 5-year breast cancer–specific survival for stage I triple-negative tumors vs 94% to 99% for hormone receptor positive and ERBB2 positive. Systemic therapy for nonmetastatic breast cancer is determined by subtype: patients with hormone receptor–positive tumors receive endocrine therapy, and a minority receive chemotherapy as well; patients with ERBB2-positive tumors receive ERBB2-targeted antibody or small-molecule inhibitor therapy combined with chemotherapy; and patients with triple-negative tumors receive chemotherapy alone. Local therapy for all patients with nonmetastatic breast cancer consists of surgical resection, with consideration of postoperative radiation if lumpectomy is performed. Increasingly, some systemic therapy is delivered before surgery. Tailoring postoperative treatment based on preoperative treatment response is under investigation. Metastatic breast cancer is treated according to subtype, with goals of prolonging life and palliating symptoms. Median overall survival for metastatic triple-negative breast cancer is approximately 1 year vs approximately 5 years for the other 2 subtypes. Conclusions and Relevance Breast cancer consists of 3 major tumor subtypes categorized according to estrogen or progesterone receptor expression and ERBB2 gene amplification. The 3 subtypes have distinct risk profiles and treatment strategies. Optimal therapy for each patient depends on tumor subtype, anatomic cancer stage, and patient preferences.

A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer

Impact of Bone-Targeted Treatments on Skeletal Morbidity and Survival in Breast Cancer

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer

Metastatic bone disease: Pathogenesis and therapeutic options

Bone targeted therapies in advanced breast cancer

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management

Optimizing the treatment of metastatic breast cancer

Breast Cancer Treatment: A Review

Metastatic Trends in Breast Cancer According to Molecular Subtypes, Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2neu Status

Molecular Mechanisms of Breast Cancer Metastases to Bone

Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment

Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis

Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report

Current and Novel Treatment Options in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Clinicopathological Characteristics and Prognostic Risk Factors of Breast Cancer Patients with Bone Metastasis

Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer

Therapeutics targeting the metastatic breast cancer bone microenvironment

Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.

Clinical Features of Breast Cancer Patients with Bone Marrow Metastasis.